Julian Harrison
Stock Analyst at BTIG
(3.82)
# 686
Out of 5,055 analysts
64
Total ratings
56.36%
Success rate
8.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORKA Oruka Therapeutics | Maintains: Buy | $56 → $63 | $26.38 | +138.82% | 3 | Nov 13, 2025 | |
| CNTB Connect Biopharma Holdings | Reiterates: Buy | $10 | $1.68 | +495.24% | 2 | Nov 13, 2025 | |
| LQDA Liquidia | Reiterates: Buy | $49 | $26.94 | +81.89% | 4 | Nov 4, 2025 | |
| VRDN Viridian Therapeutics | Reiterates: Buy | $61 | $28.49 | +114.11% | 4 | Nov 4, 2025 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $10 → $5 | $1.76 | +184.09% | 2 | Oct 29, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Buy | $82 | $83.24 | -1.49% | 3 | Oct 28, 2025 | |
| CLYM Climb Bio | Reiterates: Buy | $8 | $1.87 | +327.81% | 3 | Oct 16, 2025 | |
| TVRD Tvardi Therapeutics | Maintains: Buy | $55 → $15 | $4.11 | +264.96% | 1 | Oct 13, 2025 | |
| APGE Apogee Therapeutics | Reiterates: Buy | $115 | $62.97 | +82.63% | 2 | Oct 9, 2025 | |
| JBIO Jade Biosciences | Initiates: Buy | $28 | $9.68 | +189.26% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $120 | $100.90 | +18.93% | 3 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 | $12.56 | +576.75% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $14.73 | +171.55% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $100 | $53.95 | +85.36% | 1 | Sep 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $9.94 | +71.03% | 3 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $22.63 | +209.32% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $31.84 | +16.21% | 3 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $8.27 | +286.94% | 1 | Sep 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $25 | $17.95 | +39.28% | 2 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $7.23 | +480.91% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $17.30 | - | 3 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $33.26 | - | 2 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $9 | $1.47 | +512.24% | 5 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $2.32 | +244.83% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.37 | +2,066.26% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $1.21 | +12,296.69% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $462.30 | - | 2 | Feb 11, 2022 |
Oruka Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $56 → $63
Current: $26.38
Upside: +138.82%
Connect Biopharma Holdings
Nov 13, 2025
Reiterates: Buy
Price Target: $10
Current: $1.68
Upside: +495.24%
Liquidia
Nov 4, 2025
Reiterates: Buy
Price Target: $49
Current: $26.94
Upside: +81.89%
Viridian Therapeutics
Nov 4, 2025
Reiterates: Buy
Price Target: $61
Current: $28.49
Upside: +114.11%
Akebia Therapeutics
Oct 29, 2025
Maintains: Buy
Price Target: $10 → $5
Current: $1.76
Upside: +184.09%
Protagonist Therapeutics
Oct 28, 2025
Reiterates: Buy
Price Target: $82
Current: $83.24
Upside: -1.49%
Climb Bio
Oct 16, 2025
Reiterates: Buy
Price Target: $8
Current: $1.87
Upside: +327.81%
Tvardi Therapeutics
Oct 13, 2025
Maintains: Buy
Price Target: $55 → $15
Current: $4.11
Upside: +264.96%
Apogee Therapeutics
Oct 9, 2025
Reiterates: Buy
Price Target: $115
Current: $62.97
Upside: +82.63%
Jade Biosciences
Oct 9, 2025
Initiates: Buy
Price Target: $28
Current: $9.68
Upside: +189.26%
Oct 7, 2025
Maintains: Buy
Price Target: $112 → $120
Current: $100.90
Upside: +18.93%
Sep 29, 2025
Downgrades: Neutral
Price Target: $85
Current: $12.56
Upside: +576.75%
Sep 29, 2025
Reiterates: Buy
Price Target: $40
Current: $14.73
Upside: +171.55%
Sep 19, 2025
Reiterates: Buy
Price Target: $100
Current: $53.95
Upside: +85.36%
Sep 18, 2025
Reiterates: Buy
Price Target: $17
Current: $9.94
Upside: +71.03%
Sep 16, 2025
Reiterates: Buy
Price Target: $70
Current: $22.63
Upside: +209.32%
Sep 12, 2025
Maintains: Buy
Price Target: $30 → $37
Current: $31.84
Upside: +16.21%
Sep 10, 2025
Reiterates: Buy
Price Target: $32
Current: $8.27
Upside: +286.94%
Jun 27, 2025
Maintains: Buy
Price Target: $24 → $25
Current: $17.95
Upside: +39.28%
Dec 19, 2024
Initiates: Buy
Price Target: $42
Current: $7.23
Upside: +480.91%
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $17.30
Upside: -
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $33.26
Upside: -
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $1.47
Upside: +512.24%
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $2.32
Upside: +244.83%
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $0.37
Upside: +2,066.26%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $1.21
Upside: +12,296.69%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $462.30
Upside: -